Aligos Therapeutics（NASDAQ:ALGS）報告季度每股虧損 $(13.08)，比分析師的共識預期 $(2.30) 差 468.7%。與去年同期每股虧損 $(5.50) 相比，這一數據下降了 137.82%。公司報告季度銷售額爲 62.9 萬美元，超出分析師共識預期的 43.33 萬美元 45.15%。與去年同期銷售額 201 萬美元相比，這一數據下降了 68.69%。

以上內容來自Benzinga Earnings專欄，原文如下：

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(13.08) per share which missed the analyst consensus estimate of $(2.30) by 468.7 percent. This is a 137.82 percent decrease over losses of $(5.50) per share from the same period last year. The company reported quarterly sales of $629.00 thousand which beat the analyst consensus estimate of $433.33 thousand by 45.15 percent. This is a 68.69 percent decrease over sales of $2.01 million the same period last year.